WO2024161375 - HUMAN ANTI-PD-L2 ANTIBODY AND ITS USES THEREOF
National phase entry is expected:
Publication Number
WO/2024/161375
Publication Date
08.08.2024
International Application No.
PCT/IB2024/050995
International Filing Date
03.02.2024
Title **
[English]
HUMAN ANTI-PD-L2 ANTIBODY AND ITS USES THEREOF
[French]
ANTICORPS ANTI-PD-L2 HUMAIN ET SES UTILISATIONS
Applicants **
MABTREE BIOLOGICS AG
Inventors
ALEXANDER, Ratna Monica
ERUTHAYA RAJ, Andhuvan Raj
JAYACHANDRAN, Dr. Rajesh
SOOD, Dr. Chandni
Priority Data
202341007181
04.02.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3093 | |
| EPO | Filing, Examination, Granting | 25094 | |
| Japan | Filing, Examination, Granting | 3165 | |
| South Korea | Filing, Examination, Granting | 4051 | |
| USA | Filing, Examination, Granting | 10740 |
Total:
46,143
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides antibodies or antigen-binding fragments thereof which specifically bind to human PD-L2, and novel complementarity determining regions CDR1, CDR2, and CDR3 for each heavy chain and light chain of said antibodies. Said antibodies or antigen-binding fragments have application in enhancing T-cell function, and treatment of cancer and infectious diseases, acute or chronic.[French]
La présente invention concerne des anticorps ou des fragments de liaison à l'antigène de ceux-ci qui se lient spécifiquement au PD-L2 humain, et de nouvelles régions de détermination de complémentarité CDR1, CDR2 et CDR3 pour chaque chaîne lourde et chaîne légère desdits anticorps. Lesdits anticorps ou fragments de liaison à l'antigène ont une application dans l'amélioration de la fonction des lymphocytes T, et le traitement du cancer et de maladies infectieuses, aiguës ou chroniques.